Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) EPS (Basic) (2020 - 2025)

Historic EPS (Basic) for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $0.14.

  • Tango Therapeutics' EPS (Basic) rose 15185.19% to $0.14 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.91, marking a year-over-year increase of 2155.17%. This contributed to the annual value of -$1.19 for FY2024, which is 1088.63% down from last year.
  • Per Tango Therapeutics' latest filing, its EPS (Basic) stood at $0.14 for Q3 2025, which was up 15185.19% from -$0.35 recorded in Q2 2025.
  • Over the past 5 years, Tango Therapeutics' EPS (Basic) peaked at $0.14 during Q3 2025, and registered a low of -$0.36 during Q1 2025.
  • For the 5-year period, Tango Therapeutics' EPS (Basic) averaged around -$0.27, with its median value being -$0.29 (2021).
  • Per our database at Business Quant, Tango Therapeutics' EPS (Basic) plummeted by 911512.0% in 2021 and then skyrocketed by 15185.19% in 2025.
  • Over the past 5 years, Tango Therapeutics' EPS (Basic) (Quarter) stood at -$0.36 in 2021, then increased by 7.07% to -$0.33 in 2022, then rose by 1.47% to -$0.33 in 2023, then dropped by 5.95% to -$0.34 in 2024, then surged by 140.64% to $0.14 in 2025.
  • Its EPS (Basic) was $0.14 in Q3 2025, compared to -$0.35 in Q2 2025 and -$0.36 in Q1 2025.